Oncolytics Biotech Inc. announces positive interim results from the Phase 1/2 GOBLET trial evaluating the combination of perolep and atezolizumab in second-line patients with unresectable anal canal squamous cell carcinoma, led by Dirk Arnold, MD. It was announced that it was announced. Director of the Asklepios Oncology Center in Hamburg and principal investigator of the GOBLET trial, said this in an oral presentation at the 2nd International Multidisciplinary Congress on Anal Cancer (IMACC) 2023 in Rome, Italy. Ta. The positive interim data from the phase 2 GOBLET anal cancer cohort presented at the IMACC meeting is very exciting for the company and suggests the potential of perolep in gastrointestinal cancer. These results met prespecified success criteria for the cohort and exceeded previous control results in similar patient populations (1-7).
Menu
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
It’s great that you are getting ideas from this article as
well as from our argument made at this time.
Wow, that’s what I was exploring for, what a stuff! existing here at this website, thanks admin of this web site.
Wow, awesome blog structure! How lengthy have you been running a blog for?
you made blogging look easy. The full glance of your site is great, let alone
the content material!
Thank you a bunch for sharing this with all of us you really understand what you’re speaking about!
Bookmarked. Please additionally talk over with my website =).
We will have a hyperlink change arrangement among us